| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5569652 | BAYER HLTHCARE | Dihydrospirorenone as an antiandrogen |
Oct, 2013
(10 years ago) | |
| US6933395 | BAYER HLTHCARE | PROCESSING FOR PRODUCING OF DROSPIRENONE (6β, 7β, 15β, 16β-DIMETHYLENE-3-OXO-17α-PREGN-4-EN-21, 17-CARBOLACTONE, DRSP) AS WELL AS 7α-(3-HYDOXY-1-PROPLY)-6β, 7β; 15β, 16β-DIMETHYLENE-5β-ANDROSTANE-3β, 5,17β-TRIOL(ZK 92836) AND 6β, 7β; 15β, 16β-DIMETHYLENE-5β-HYDROXY |
Aug, 2017
(6 years ago) | |
| US6787531 | BAYER HLTHCARE | Pharmaceutical composition for use as a contraceptive |
Aug, 2020
(3 years ago) | |
Yasmin is owned by Bayer Hlthcare.
Yasmin contains Drospirenone; Ethinyl Estradiol.
Yasmin has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Yasmin are:
- US5569652
- US6933395
- US6787531
Yasmin was authorised for market use on 11 May, 2001.
Yasmin is available in tablet;oral-28 dosage forms.
Yasmin can be used as prevention of pregnancy.
The generics of Yasmin are possible to be released after 31 August, 2020.
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL ingredient
Market Authorisation Date: 11 May, 2001
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL-28
How can I launch a generic of YASMIN before it's drug patent expiration?
More Information on Dosage
YASMIN family patents
